Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 10/20 | 0.74 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29057543 | 0.92 | OGA (0.71) | OGAATMMEN1KMT2AALDH1A1 | |
| SCHEMBL29057489 | 0.87 | OGA (0.64) | OGAATMMEN1KMT2AALDH1A1 | |
| SCHEMBL29057492 | 0.86 | OGA (0.79) | OGAATMMEN1KMT2ALMNA | |
| SCHEMBL29057507 | 0.86 | OGA (0.66) | OGAKMT2AALDH1A1CA1CA2 | |
| SCHEMBL27022322 | 0.85 | OGA (1.00) | OGA | |
| SCHEMBL29057423 | 0.85 | OGA (0.72) | OGAATMMEN1KMT2AALDH1A1 | |
| SCHEMBL29057479 | 0.85 | OGA (0.72) | OGAATMKMT2AALDH1A1LMNA | |
| SCHEMBL29057449 | 0.82 | OGA (0.61) | OGAATMMEN1KMT2AALDH1A1 | |
| SCHEMBL29057464 | 0.81 | OGA (0.72) | OGAMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL29057521 | 0.80 | ALDH1A1 (0.65) | OGAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116438167-A | Compounds having O-GlcNAc enzyme inhibitory activity and uses thereof | 美迪福伦DBT有限公司 | 2023-07-14 | — | — | CN | disclosed |